|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Aggregation-induced emission (ALE) dye loaded polymer nanoparticles for gene silencing in pancreatic cancer and their in vitro and in vivo biocompatibility evaluation显示文摘 | Rui Hu Chengbin Yang Yucheng Wang Guimiao Lin Wei Qin Qingling Ouyang Wing-Cheung Law Quoc Toan Nguyen Ho Sup Yoon Xiaomei Wang Ken-Tye Yong Ben Zhong Tang | 2015 | Nano Research2015，8，5： | 4 |
| 2 | Biodegradable nanocarriers for small interfering ribonucleic acid (siRNA) co-delivery strategy increase the chemosensitivity of pancreatic cancer cells to gemcitabine显示文摘Ribonucleic acid (RNA) interference (RNAi) therapies are promising cancertreatment modalities that can specifically target abnormal proto-oncogenes, thusimproving the therapeutic effect. For the treatment of pancreatic cancer, targetingone mutant proto-oncogene by RNAi usually does not yield the desired therapeuticefficiency. Both K-ras gene mutations and Notch1 overexpression are commonsymptoms in pancreatic cancer patients, and play a crucial role in pancreaticcancer cell drug resistance. In this study, biodegradable charged polyester-basedvectors (BCPVs) were synthesized for the co-delivery of K-ras and Notch1 smallinterfering ribonucleic acid (siRNA) into MiaPaCa-2 cells (pancreatic cancercell line) to overcome drug resistance to gemcitabine (GEM), a first-line chem-otherapeutic drug used in the clinic. BCPVs could effectively absorb negative siRNAto form a capsule-like structure, prevent siRNA from nuclease digestion in theserum, and promote effective siRNA cell internalization and endosomal escape.Through K-ras and Notch1 gene silencing in MiaPaCa-2 cells, BCPV-siRNAKsiRNAN^tcm nanocomplexes effectively reversed the epithelia-mesenchymaltransition (EMT) in MiaPaCa-2 cells, thereby greatly enhancing the sensitivity ofMiaPaCa-2 cells to GEM. MiaPaCa-2 cell proliferation, migration, and invasionwere effectively inhibited, and cell apoptosis was also significantly enhanced bythe synergistic antitumor effect of BCPV-siRNAK siRNAN^t~l nanocomplexesand GEM. These results suggest that this combination RNAi therapy can be usedto improve cancer cell sensitivity to chemotherapeutic drugs. Specifically, thisnewly develooed strate^v has a great potential for treating pancreatic cancer. | Chengbin Yang Kok Ken Chan Wen-Jen Lin Alana Mauluidy Soehartono Guimiao Lin Huiting Toh Ho Sup Yoon Chih-Kuang Chen Ken-Tye Yong | 2017 | Nano Research2017，10，9： | 3 |
| 3 | Early growth re-sponse protein-1 promoter-mediated synergistic antitumor effect ofhTERTC27 gene therapy and 5 -Flurorouracil on nasopharyngealcarcinoma显示文摘 | Guimiao Lin Marie Chia-Mi Lin Suxia | 2012 | Cancer biotherapy & radiopharmaceuticals2012，27，7： | 1 |
| 4 | Early growth response protein - 1 promoter - mediated synergistic anti - tumor effect of hTERTC27 gene therapy and 5 - Flu- rorouracil on nasopharyngeal carcinoma显示文摘 | Guimiao Lin Marie Chia - Mi Lin Suxia | 2012 | Cancer biother- apy & radiopharmaceuticals2012，27，7： | 1 |
| 5 | Synthetic and immunological studies on the OCT4 immunodominant motif antigen-based anti-cancer vaccine显示文摘Objective:Cancer stem cell is one of the important causes of tumorigenesis as well as a drug target in the treatment of malignant tumor.However,at present,there is no immune vaccine targeting these cells.Octamer-binding transcription factor 4(OCT4),a marker of embryonic stem cells and germ cells,often highly expresses in the early stages of tumorigenesis and is therefore a good candidate for cancer vaccine development.Methods:To identify the optimal carrier and adjuvant combination,we chemically synthesized and linked three different OCT4 epitope antigens to a carrier protein,keyhole limpet hemocyanin(KLH),combined with Toll-like receptor 9 agonist(TLR9).Results:Immunization with OCT4-3+TLR9 produced the strongest immune response in mice.In prevention assays,significant tumor growth inhibition was achieved in BABL/c mice treated with OCT4-3+TLR9(P<0.01).Importantly,the results showed that cytotoxic T lymphocyte activity and the inhibition of tumor growth were enhanced in mice immunized with OCT4-3 combined with TLR9.Meanwhile,multiple cytokines[such as interferon(IFN)-γ(P<0.05),interleukin(IL)-12(P<0.05),IL-2(P<0.01),and IL-6(P<0.05)]promoting cellular immune responses were shown to be greatly enhanced in mice immunized with OCT4-3+TLR9.Moreover,we considered safety considerations in terms of the composition of the vaccines to help facilitate the development of effective next-generation vaccines.Conclusions:Collectively,these experiments demonstrated that combination therapy with TLR9 agonist induced a tumor-specific adaptive immune response,leading to the suppression of primary tumor growth in testis embryonic carcinoma. | Tingting Chen Kan Liu Jiangyao Xu Tianying Zhan Maixian Liu Li Li Zhiwen Yang Shuping Yuan Wenyi Zou Guimiao Lin Dennis ACarson Christina CNWu Xiaomei Wang | 2020 | Cancer Biology & Medicine2020，17，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员